DeepMed Research

ASTELLAS PHARMA KOREA, INC.

🇰🇷South Korea

Country: 🇰🇷South Korea

Ownership: Subsidiary

Employees: -

Market Cap: -

Website: http://www.astellas.co.kr

Clinical Trials

A Study to Observe the Safety of VYLOY (Zolbetuximab) in People in South Korea With Gastric or Gastroesophageal Junction Cancer.

Recruiting

Conditions: Locally Advanced Unresectable Gastroesophageal Junction (GEJ) Adenocarcinoma or Cancer
Locally Advanced Unresectable Gastric Adenocarcinoma or Cancer
Metastatic Gastric Adenocarcinoma or Cancer
Metastatic Gastroesophageal Junction (GEJ) Adenocarcinoma

Interventions: Drug: zolbetuximab

First Posted Date: 2025-03-30

Last Posted Date: 2025-05-01

Lead Sponsor: Astellas Pharma Korea, Inc.

Target Recruit Count: 377

Registration Number: NCT06902545

Locations: 🇰🇷
KR82001, Seoul, Korea, Republic of

Non-Interventional Study to Establish Consensus on Management of Metastatic Hormone-Sensitive Prostate Cancer Patients

Completed

Conditions: Metastatic Hormone-Sensitive Prostate Cancer

Interventions: Other: No Intervention

First Posted Date: 2024-06-11

Last Posted Date: 2024-11-21

Lead Sponsor: Astellas Pharma Korea, Inc.

Target Recruit Count: 23

Registration Number: NCT06452212

Locations: 🇰🇷
KR82001, Seoul, Korea, Republic of

A Study to Survey Adults in South Korea With Cancer Who Receive PADCEV Injection

Recruiting

Conditions: Urothelial Cancer

Interventions: Drug: Enfortumab Vedotin

First Posted Date: 2023-08-25

Last Posted Date: 2025-05-09

Lead Sponsor: Astellas Pharma Korea, Inc.

Target Recruit Count: 235

Registration Number: NCT06011954

Locations: 🇰🇷
Site KR82006, Seoul, Korea, Republic of
🇰🇷
Site KR82011, Seoul, Korea, Republic of
🇰🇷
Site KR82001, Goyang-si, Gyeonggi-do, Korea, Republic of

and more 14 locations

A Study to Assess the Safety of Xospata in Patients With Relapsed or Refractory Acute Myeloid Leukemia (AML) With FMS-Like Tyrosine Kinase 3 (FLT3) Mutation

Active, not recruiting

Conditions: Acute Myeloid Leukemia With FMS-like Tyrosine Kinase (FLT3) Mutation

Interventions: Drug: Gilteritinib Exposure

First Posted Date: 2020-12-31

Last Posted Date: 2025-04-24

Lead Sponsor: Astellas Pharma Korea, Inc.

Target Recruit Count: 33

Registration Number: NCT04691648

Locations: 🇰🇷
Site KR82013, Wonju-si, Gangwon-do, Korea, Republic of
🇰🇷
Site KR82006, Goyang-si, Gyeonggi-do, Korea, Republic of
🇰🇷
Site KR82003, Jeollanam-do, Hwasun-gun, Korea, Republic of

and more 7 locations

A Study Comparing Biologics + Methotrexate With Biologics + Tacrolimus in Patients With Rheumatoid Arthritis (RA)

Phase 4

Completed

Conditions: Rheumatoid Arthritis (RA)

Interventions: Drug: methotrexate
Drug: tacrolimus
Biological: adalimumab
Biological: tocilizumab
Biological: abatacept

First Posted Date: 2018-11-09

Last Posted Date: 2024-10-31

Lead Sponsor: Astellas Pharma Korea, Inc.

Target Recruit Count: 21

Registration Number: NCT03737708

Locations: 🇰🇷
Site KR82003, Daegu, Korea, Republic of
🇰🇷
Site KR82007, Daegu, Korea, Republic of
🇰🇷
Site KR82002, Incheon, Korea, Republic of

and more 7 locations

Quality of Life Questionnaire Validation for Patients With Changed Tacrolimus Dosing After Kidney Transplantation

Completed

Conditions: Kidney Transplantation

Interventions: Behavioral: Qualitative interviews with participants

First Posted Date: 2018-08-09

Last Posted Date: 2024-10-21

Lead Sponsor: Astellas Pharma Korea, Inc.

Target Recruit Count: 56

Registration Number: NCT03623217

Locations: 🇰🇷
Site 1, Seoul, Korea, Republic of

A Study to Evaluate the Renal Protective Effect (Urine Albumin-to-Creatinine Ratio (UACR)), Efficacy and Safety of Ipragliflozin in Type 2 Diabetes Mellitus Patients With Albuminuria

Phase 4

Terminated

Conditions: Type 2 Diabetes Mellitus

Interventions: Drug: metformin
Drug: ipragliflozin
Drug: glimepiride

First Posted Date: 2017-04-18

Last Posted Date: 2024-11-08

Lead Sponsor: Astellas Pharma Korea, Inc.

Target Recruit Count: 33

Registration Number: NCT03118713

Locations: 🇰🇷
Site 11, Guri-si, Korea, Republic of
🇰🇷
Site 01, Seoul, Korea, Republic of
🇰🇷
Site 09, Seoul, Korea, Republic of

and more 5 locations

A Study to Assess the Safety and Efficacy of a Tacrolimus Based Immunosuppressive Regimen in Stable Kidney Transplant Recipients Converted From Cyclosporine Based Immunosuppressive Regimen

Phase 4

Terminated

Conditions: Kidney Transplantation

Interventions: Drug: Tacrolimus

First Posted Date: 2016-11-15

Last Posted Date: 2016-11-23

Lead Sponsor: Astellas Pharma Korea, Inc.

Target Recruit Count: 13

Registration Number: NCT02963103

Locations: 🇰🇷
KR00001, Seoul, Korea, Republic of

Study to Assess the Safety and Efficacy of Tacrolimus (Prograf Capsule/Injection) and Methotrexate (MTX) Combination Therapy for Prevention of Graft Versus Host Disease (GVHD) in Patients Who Received Peripheral Hematopoietic Stem Cell Transplantation From a Sibling Donor

Phase 4

Completed

Conditions: Graft Versus Host Disease

Interventions: Drug: Prograf
Drug: Methotrexate
Drug: Cyclosporine

First Posted Date: 2016-01-21

Last Posted Date: 2016-03-01

Lead Sponsor: Astellas Pharma Korea, Inc.

Target Recruit Count: 39

Registration Number: NCT02660684

A Study to Assess the Efficacy and Safety of ASP1941 in Subjects With Type 2 Diabetes Mellitus Who Have Inadequate Glycemic Control on Metformin and Sitagliptin

Phase 3

Completed

Conditions: Type 2 Diabetes Mellitus

Interventions: Drug: Placebo
Drug: ASP1941

First Posted Date: 2015-05-22

Last Posted Date: 2024-11-11

Lead Sponsor: Astellas Pharma Korea, Inc.

Target Recruit Count: 143

Registration Number: NCT02452632

Locations: 🇰🇷
Site KR00002, Busan, Korea, Republic of
🇰🇷
Site KR00007, Daegu, Korea, Republic of
🇰🇷
Site KR00001, Seoul, Korea, Republic of

and more 19 locations

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy